Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes-Reference-Cited by-同舟云学术

Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes

Published:2017-06-08 Issue:11 Volume:19 Page:1521-1528
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Guzman Cristina B.¹,Zhang Xiaotian M.²,Liu Rong¹,Regev Arie¹,Shankar Sudha¹,Garhyan Parag¹,Pillai Sreekumar G.¹^ORCID,Kazda Christof³,Chalasani Naga⁴,Hardy Thomas A.¹

Affiliation:

1. Eli Lilly and Company; Indianapolis Indiana

2. Eli Lilly Canada Inc; Toronto Ontario Canada

3. Eli Lilly and Company; Neuilly-sur-Seine France

4. Division of Gastroenterology and Hepatology; Department of Medicine, Indiana University School of Medicine; Indianapolis Indiana

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12958/fullpdf

Reference26 articles.

1. Glucagon-early breakthroughs and recent discoveries;Ahrén;Peptides,2015

2. Extra-helical binding site of a glucagon receptor antagonist;Jazayeri;Nature,2016

3. Glucagon antagonism as a potential therapeutic target in type 2 diabetes;Bagger;Diabetes Obes Metab,2011

4. Glucagon and the A cell: physiology and pathophysiology (first two parts);Unger;N Engl J Med,1981

5. The glucagon receptor is required for the adaptive metabolic response to fasting;Longuet;Cell Metab,2008

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic glucose metabolism in the steatotic liver;Nature Reviews Gastroenterology & Hepatology;2024-02-02

2. Disruption of glucagon receptor induces single α-cell hypersecretion through upregulation of VGF;2024-01-26

3. Emerging glucagon-based therapies in diabetes mellitus: Toward a better future in diabetes care;Journal of Diabetology;2024-01-06

4. Glucagon and the metabolic syndrome;Metabolic Syndrome;2024

5. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients;Molecular Metabolism;2024-01